Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-alpha
AssigneeMount Sinai Hospital
InventorsIsabella Caniggia, Martin Post
Life of this patent
Estimating the term…
Abstract
The invention relates to reagents and methods for detecting, diagnosing and screening for conditions associated with hydroxylated hypoxia inducible factor 1-α (HIF-1α). The invention also relates to novel monoclonal antibodies specific for hydroxylated HIF-1α, or binding fragments thereof, and related nucleic acids, vectors, cells and compositions, as well as methods of using the antibodies in methods of the invention.
Claims18
A monoclonal antibody or an antigen recognition domain that specifically binds human HIF-1α comprising hydroxylated proline 402, or hydroxylated proline 402 and hydroxylated proline 564.
An isolated antibody or antigen recognition domain thereof comprising
- (a) a light chain variable sequence of SEQ ID NO. 13, 14, 25, 26, 30, 31, 7, 8, 19, 20, 36, or 37, or a sequence having at least 90% identity therewith;
- or
- (b) a heavy chain variable sequence of SEQ ID NO. 16, 17, 27, 28, 33, 34, 10, 11, 22, 23, 39, 40, or a sequence having at least 90% identity therewith.
(canceled)
A method for diagnosing a pregnancy-related condition in a subject at risk of such a condition comprising:
- (a) contacting a sample from a subject with a reagent capable of determining the status of one or more Hydroxylated HIF Biomarkers;
- and
- (b) providing a diagnosis of the condition in the subject based on a difference in the status of the Hydroxylated HIF Biomarkers in the sample from the subject over a control obtained from similar samples taken from subjects who do not have the condition or have a different stage of the condition, or from the subject at a different time,
- wherein the Hydroxylated HIF Biomarkers comprise HIF-1α hydroxylated at one or both of proline 402 and proline 564, or portions thereof.
(canceled)
Dependencies are inferred from the claim text.